JP2024525612A5 - - Google Patents
Info
- Publication number
- JP2024525612A5 JP2024525612A5 JP2024500480A JP2024500480A JP2024525612A5 JP 2024525612 A5 JP2024525612 A5 JP 2024525612A5 JP 2024500480 A JP2024500480 A JP 2024500480A JP 2024500480 A JP2024500480 A JP 2024500480A JP 2024525612 A5 JP2024525612 A5 JP 2024525612A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- oligonucleotide
- optionally
- complex according
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163220030P | 2021-07-09 | 2021-07-09 | |
| US63/220,030 | 2021-07-09 | ||
| PCT/US2022/073534 WO2023283619A2 (en) | 2021-07-09 | 2022-07-08 | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525612A JP2024525612A (ja) | 2024-07-12 |
| JP2024525612A5 true JP2024525612A5 (OSRAM) | 2025-07-17 |
Family
ID=84802094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500480A Pending JP2024525612A (ja) | 2021-07-09 | 2022-07-08 | 筋標的化複合体およびジストロフィノパチーを処置するためのその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240382609A1 (OSRAM) |
| EP (1) | EP4367142A4 (OSRAM) |
| JP (1) | JP2024525612A (OSRAM) |
| KR (1) | KR20240032946A (OSRAM) |
| CN (1) | CN118401553A (OSRAM) |
| CA (1) | CA3226300A1 (OSRAM) |
| IL (1) | IL309911A (OSRAM) |
| WO (1) | WO2023283619A2 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP7611825B2 (ja) | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| US20220193250A1 (en) | 2018-08-02 | 2022-06-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12624120B2 (en) | 2020-01-31 | 2026-05-12 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TfR) antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| CN117980006A (zh) | 2021-07-09 | 2024-05-03 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物和制剂 |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
| KR20260044219A (ko) | 2023-07-21 | 2026-04-01 | 매로우 테라퓨틱스, 인크. | 조혈 세포 표적화 접합체 및 관련 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2203173B1 (en) * | 2007-10-26 | 2015-12-23 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
| JP2021526796A (ja) * | 2018-06-13 | 2021-10-11 | サレプタ セラピューティクス， インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマー |
| JP7611825B2 (ja) * | 2018-08-02 | 2025-01-10 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| IL319265A (en) * | 2018-12-21 | 2025-04-01 | Avidity Biosciences Inc | Anti-transferrin receptor antibodies and their uses |
| US20230285586A1 (en) * | 2020-07-23 | 2023-09-14 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
-
2022
- 2022-07-08 WO PCT/US2022/073534 patent/WO2023283619A2/en not_active Ceased
- 2022-07-08 JP JP2024500480A patent/JP2024525612A/ja active Pending
- 2022-07-08 US US18/577,472 patent/US20240382609A1/en active Pending
- 2022-07-08 CN CN202280060769.5A patent/CN118401553A/zh active Pending
- 2022-07-08 CA CA3226300A patent/CA3226300A1/en active Pending
- 2022-07-08 EP EP22838590.2A patent/EP4367142A4/en active Pending
- 2022-07-08 KR KR1020247004294A patent/KR20240032946A/ko active Pending
- 2022-07-08 IL IL309911A patent/IL309911A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024525611A5 (OSRAM) | ||
| JP2024525613A5 (OSRAM) | ||
| JP2024527362A5 (OSRAM) | ||
| JP2024525610A5 (OSRAM) | ||
| IL309937A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309911A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309935A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309912A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| IL309909A (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023510350A5 (OSRAM) | ||
| US11771776B2 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2023535073A5 (OSRAM) | ||
| US20240117356A1 (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| US20250099603A9 (en) | Muscle targeting complexes and uses thereof for treating friedreich's ataxia | |
| IL309936A (en) | Muscle targeting complexes and formulations for the treatment of dystrophinopathy | |
| JP2024540199A (ja) | ジストロフィノパチーを処置するための筋標的化複合体 | |
| US20240398968A1 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies | |
| JP2026503873A (ja) | Ｄｍｄ遺伝子のエクソン４５をスキップするための筋肉標的化複合体およびその使用 | |
| JP2024524222A5 (OSRAM) | ||
| JP2024540199A5 (OSRAM) | ||
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| IL322946A (en) | Methods and compositions for inhibiting the progression of intramuscular fibrosis | |
| JP2024534880A5 (OSRAM) | ||
| WO2020178258A1 (en) | Intracellular targeting of molecules | |
| US12629426B2 (en) | Muscle targeting complexes and uses thereof for treating dystrophinopathies |